The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
RECRUITINGHunan Cancer Hospital
Changsha, Hunan, China
RECRUITINGThe maximum concentration (Cmax) for SHR-A1811
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
The maximum concentration (Cmax) for payload
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Area under the concentration curve from time 0 to 16 days (AUC0-16d) for SHR-A1811
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Area under the concentration curve from time 0 to 16 days (AUC0-16d) for payload
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Time to maximum plasma concentration (Tmax)
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Terminal half-life (t1/2)
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Area under the concentration curve from time 0 to infinity (AUCinf)
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Clearance (CL)
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Volume of distribution at steady state (Vss)
Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.
Incidence and severity of adverse events
Time frame: From the beginning of screening period to approximately 3 months after the last dose.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.